Cancer Vaccines Market size was valued at USD 9.36 billion in 2023 and is set to exceed USD 38.99 billion by 2036, registering over 11.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cancer vaccines is evaluated at USD 10.23 billion.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
11.6% |
Base Year Market Size (2023) |
USD 9.36 billion |
Forecast Year Market Size (2036) |
USD 38.99 billion |
Regional Scope |
|
The market is segmented by vaccine, by indication, by technology and by region, out of which, the vaccine segment is segmented into therapeutic cancer vaccines and preventive cancer vaccines. The segment for preventive cancer vaccines is anticipated to hold the largest share in the cancer vaccines market on account of growing demand for these vaccines by people for prevention of cancer. Preventive cancer vaccines reduce the risk of infection by cancer causing organisms and help the body to build up immunity against them by creating antibodies. The therapeutic cancer vaccines segment is predicted to grow at the highest rate over the forecast period as a result of high demand for vaccines for the treatment of cancer. Based on technology, the cancer vaccines market is segmented into recombinant vaccine, dendritic cells vaccine, whole cell vaccine, adjuvant vaccine and viral vector & DNA vaccine. According to the National Cancer Institute, the vaccines for prevention of disease causing HPV that are approved for use in the United States include Cervarix, Gardasil and Gardasil 9. These prevent infection from HPV type 16 and 18, which are estimated to cause around 70% of all cervical cancers.
Our in-depth analysis of the global market includes the following segments
By Vaccine |
|
By Indication |
|
By Technology |
|
On the basis of regional analysis, the cancer vaccines market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America industry is set to account for largest revenue share by 2036, as a result of highly developed healthcare infrastructure as well as presence of leading key players in the region. The market in Europe is anticipated to hold the second largest share on account of highly advanced technology being used in the region. On the other hand, the market in Asia Pacific is projected to grow at the highest rate over the forecast period as a result of rising cases of cancer in the region and growing presence of leading pharmaceutical and biotechnology companies in the region, especially in China, India and Japan.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?